Berlin-Chemie AG Menarini Group clinical trials

Acquired by Menarini Group

The registry lists 8 studies whose lead sponsor is Berlin-Chemie AG Menarini Group. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 8 of 8. All Menarini Group studies →

• A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions:RecruitingNCT07201584Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting ConditionsRecruitingNCT07156916Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady StateActive, not recruitingNCT07146711Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed ConditionsActive, not recruitingNCT07091669Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral SuspensionCompletedNCT07036861Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose AdministrationCompletedNCT06547242Phase 1

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVTCompletedNCT01880216Phase 3

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group

• Effects of Nebivolol Versus Metoprolol Succinate on Endothelial FunctionCompletedNCT01248338Phase 4

  Sponsor listed in the registry: Berlin-Chemie AG Menarini Group · Berlin-Chemie AG Menarini Group — acquired company within the Menarini Group group